Abstract
Rats were treated for 3 days with the selective D 1 dopamine receptor antagonist SCH23390 (250 μg/kg i.p., 3 × daily), the selective D 2 dopamine receptor antagonist YM-09151-M (500 μg/kg i.p., 2 × daily), or saline. The levels of striatal proenkephalin mRNA were then assayed by in-situ hybridisation histochemistry, using a synthetic oligonucleotide probe. Following YM-09151-M treatment, proenkephalin mRNA levels were dramatically raised in the striatum, compared to animals receiving vehicle injections. In contrast, rats treated with SCH23390 showed decreased striatal levels of proenkephalin mRNA. The results demonstrate that selective D 2 receptor blockade leads to enhanced proenkephalin gene expression in rat striatum, while selective D 1 receptor antagonism has the opposite effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
